SciELO - Scientific Electronic Library Online

 
vol.137 número5Síndrome metabólico: Bases clínicas y fisiopatológicas para un enfoque terapéutico racional¿Podemos mantenernos actualizados en medicina en el siglo XXI? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

MOLINOS-CASTRO, Sonia; PESQUEIRA-FONTAN, Paula María  y  DIAZ-PEROMINGO, José Antonio. Pharmacological treatment of hereditary haemorrhagic telangiectasia. Rev. méd. Chile [online]. 2009, vol.137, n.5, pp. 695-700. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872009000500015.

Hereditary hemorrhagic telangiectasia (HHT) of Rendu-Osler-Weber disease is a multi system vascular dysplasia characterized by the presence of multiple telangiectasias, mainly affecting mucosal tissue and arterial-venous connections. It commonly affects lungs, liver and central nervous system. Bleeding is the most common symptom and its treatment can be surgical or pharmacological. We herein review the systemic therapy that attempts to minimize bleeding as well as blood transfusion therapy. Blood therapy and fibrinolytic treatment especially aminocaproic acid and tranexamic acid are discussed. Danazol, hormone therapy and other less common drugs used in the treatment of HHT are also reviewed.

Palabras clave : Blood transfusions; Fibrinolysis; Telangiectasia, hereditary hemorrhagic.

        · texto en Español     · pdf en Español